| Caroline Taylor Mears, DO | |
|
401 Castle Creek Rd, Aspen, CO 81611-1159 | |
| (970) 279-4111 | |
| Not Available |
| Full Name | Caroline Taylor Mears |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Location | 401 Castle Creek Rd, Aspen, Colorado |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164981270 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | DR0069359 (Colorado) | Primary |
| Entity Name | Aspen Valley Hospital District |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518960814 PECOS PAC ID: 9234123266 Enrollment ID: O20040413000642 |
News Archive
BioLife Solutions Inc. has announced that it has submitted a Master File to the United States Food and Drug Administration (FDA) for the Company's HypoThermosol preservation media product.
Afatinib (trade name: Giotrif) has been approved since April 2016 for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) of squamous histology who have already received chemotherapy.
NanoBio Corporation announced today that it has received a $6M grant from the Bill & Melinda Gates Foundation to support the development of a safe and effective intranasal vaccine for Respiratory Syncytial Virus (RSV).
An Australian-owned obesity drug, developed by Melbourne-based biotechnology company Metabolic Pharmaceuticals Limited, is set to enter final human trials next year after successfully completing a Phase 2b human trial which proved that the drug induces weight loss and is very well tolerated with no evidence of the side effects commonly experienced with existing obesity drugs.
› Verified 3 days ago
| Entity Name | Aspen Valley Hospital Clinics, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003306168 PECOS PAC ID: 3375891013 Enrollment ID: O20180813000798 |
News Archive
BioLife Solutions Inc. has announced that it has submitted a Master File to the United States Food and Drug Administration (FDA) for the Company's HypoThermosol preservation media product.
Afatinib (trade name: Giotrif) has been approved since April 2016 for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) of squamous histology who have already received chemotherapy.
NanoBio Corporation announced today that it has received a $6M grant from the Bill & Melinda Gates Foundation to support the development of a safe and effective intranasal vaccine for Respiratory Syncytial Virus (RSV).
An Australian-owned obesity drug, developed by Melbourne-based biotechnology company Metabolic Pharmaceuticals Limited, is set to enter final human trials next year after successfully completing a Phase 2b human trial which proved that the drug induces weight loss and is very well tolerated with no evidence of the side effects commonly experienced with existing obesity drugs.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Caroline Taylor Mears, DO 401 Castle Creek Rd, Aspen, CO 81611-1159 Ph: (757) 705-0924 | Caroline Taylor Mears, DO 401 Castle Creek Rd, Aspen, CO 81611-1159 Ph: (970) 279-4111 |
News Archive
BioLife Solutions Inc. has announced that it has submitted a Master File to the United States Food and Drug Administration (FDA) for the Company's HypoThermosol preservation media product.
Afatinib (trade name: Giotrif) has been approved since April 2016 for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) of squamous histology who have already received chemotherapy.
NanoBio Corporation announced today that it has received a $6M grant from the Bill & Melinda Gates Foundation to support the development of a safe and effective intranasal vaccine for Respiratory Syncytial Virus (RSV).
An Australian-owned obesity drug, developed by Melbourne-based biotechnology company Metabolic Pharmaceuticals Limited, is set to enter final human trials next year after successfully completing a Phase 2b human trial which proved that the drug induces weight loss and is very well tolerated with no evidence of the side effects commonly experienced with existing obesity drugs.
› Verified 3 days ago
Carl Schiller, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 100 E Main St, Ste 201, Aspen, CO 81611 Phone: 970-544-1131 | |
Susan Zimet, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 600 E Main St Ste 103, Aspen, CO 81611 Phone: 970-544-1131 Fax: 844-384-5032 | |
Joseph Schuller, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 401 Castle Creek Rd, Aspen, CO 81611 Phone: 970-544-7385 | |
Dr. Timothy C Rodell, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 201 Midland Ave, Aspen, CO 81611 Phone: 970-948-5844 Fax: 970-948-5844 | |
Eugene Howard Seymour, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 390 N Spring St, Aspen, CO 81611 Phone: 310-486-5677 Fax: 630-604-6402 | |
Barry Mink, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 100 E Main St, Ste 201, Aspen, CO 81611 Phone: 970-544-1131 |